{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 56,
  "pageCount": 60,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "Shows two distinct experiments: DFAM-68555 (leukemia burden) and MOLM-13 (tumor volume).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/56",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-56",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.1,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Whole Blood DFAM-68555 Day 14",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebfb3215-817e-41e2-b61b-3064d510954f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "MOLM-13 AML XGs",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a41d280d-6658-4a0b-a299-819c11d29e94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.6,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Single dose of KT-253 in combination with daily dosing of Venetoclax achieves sustained tumor regression in MOLM-13 xenograft model",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3dbfc40d-c675-43e9-81da-1da8d96dee2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.08,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "DFAM-6855 Characteristics: M5a (monoblastic); Mutations: FLT3, MLL3. KT-253 3 mg/kg Q3W dosing significantly reduces hCD45+ cells in Peripheral Blood",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f078175f-30cd-49a2-88d8-b5d9e9f4d023",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.15,
        "y": 0.05
      },
      "kind": "title",
      "text": "Strong Single Agent and Combinatorial Activity in Venetoclax Resistant AML Models",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "184d04fb-b80c-44b0-ac58-cf46edd4378a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}